Lexicon Pharmaceuticals, Inc. stock is up 22.77% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 23 December’s closed higher than November.
Lexicon Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the. treatment of neuropathic pain.